Hold Rating for PTC Therapeutics Amidst Regulatory Hurdles with Translarna
Leerink Partners analyst Joseph Schwartz has maintained their neutral stance on PTCT stock, giving a Hold rating on October 11. Joseph ...
FiercePharma3d
EU drug reviewers back Novo Nordisk’s FDA-rejected hemophilia drug, snub PTC’s Translarna again
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
Pharmabiz1d
EMA re-confirms non-renewal of conditional marketing authorisation of Duchenne muscular dystrophy medicine, Translarna
EMA re-confirms non-renewal of conditional marketing authorisation of Duchenne muscular dystrophy medicine, Translarna: Amsterdam, The Netherlands Monday, October 21, 2024, 10:00 ...
CHMP Maintains Negative Opinion on Translarna™ Reexamination
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal ...
PTC Therapeutics: CHMP Again Recommends Against Translarna Renewal
PTC Therapeutics has suffered another setback in its bid to keep its Duchenne muscular dystrophy drug Translarna on the market in Europe. PTC on Friday said the European Medicines Agency's Committee ...
PTC: CHMP Maintains Negative Opinion On Renewal Of Conditional Marketing Authorization Of Translarna
PTC Therapeutics (PTCT) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has ...
Stockhouse4d
CHMP Maintains Negative Opinion on Translarna(TM) Reexamination
Translarna (ataluren), discovered and developed by PTC Therapeutics, is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders ...
Le Lézard3d
CHMP Maintains Negative Opinion on Translarnatm Reexamination
PTC Therapeutics, Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European ...